129 related articles for article (PubMed ID: 29491259)
1. Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor.
Iikubo K; Kondoh Y; Shimada I; Matsuya T; Mori K; Ueno Y; Okada M
Chem Pharm Bull (Tokyo); 2018; 66(3):251-262. PubMed ID: 29491259
[TBL] [Abstract][Full Text] [Related]
2. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
3. 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.
Han M; Shen J; Wang L; Wang Y; Zhai X; Li Y; Liu M; Li Z; Zuo D; Wu Y
Chem Biol Interact; 2018 Mar; 284():24-31. PubMed ID: 29458018
[TBL] [Abstract][Full Text] [Related]
4. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
7. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
8. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.
Achary R; Mathi GR; Lee DH; Yun CS; Lee CO; Kim HR; Park CH; Kim P; Hwang JY
Bioorg Med Chem Lett; 2017 May; 27(10):2185-2191. PubMed ID: 28385505
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inhibitors.
Iikubo K; Kurosawa K; Matsuya T; Kondoh Y; Kamikawa A; Moritomo A; Iwai Y; Tomiyama H; Shimada I
Bioorg Med Chem; 2019 Apr; 27(8):1683-1692. PubMed ID: 30878193
[TBL] [Abstract][Full Text] [Related]
10. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.
Lee HJ; Latif M; Choe H; Ali I; Lee HK; Yang EH; Yun JI; Chae CH; Jung JK; Kim HR; Lee CO; Park CH; Lee K
Arch Pharm Res; 2014; 37(9):1130-8. PubMed ID: 24446111
[TBL] [Abstract][Full Text] [Related]
11. Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026.
Takeguchi K; Hirakura Y; Yamazaki K; Shimada I; Ieda S; Okada M; Takiyama H
Chem Pharm Bull (Tokyo); 2015; 63(6):418-22. PubMed ID: 26027465
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
James N; Ramanathan K
Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
[TBL] [Abstract][Full Text] [Related]
14. Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer.
Liu J; Ma S
Curr Med Chem; 2017; 24(6):590-613. PubMed ID: 27804873
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.
Michellys PY; Chen B; Jiang T; Jin Y; Lu W; Marsilje TH; Pei W; Uno T; Zhu X; Wu B; Nguyen TN; Bursulaya B; Lee C; Li N; Kim S; Tuntland T; Liu B; Sun F; Steffy A; Hood T
Bioorg Med Chem Lett; 2016 Feb; 26(3):1090-1096. PubMed ID: 26750252
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
17. Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.
Mesaros EF; Angeles TS; Albom MS; Wagner JC; Aimone LD; Wan W; Lu L; Huang Z; Olsen M; Kordwitz E; Haltiwanger RC; Landis AJ; Cheng M; Ruggeri BA; Ator MA; Dorsey BD; Ott GR
Bioorg Med Chem Lett; 2015 Mar; 25(5):1047-52. PubMed ID: 25655723
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.
Marsilje TH; Pei W; Chen B; Lu W; Uno T; Jin Y; Jiang T; Kim S; Li N; Warmuth M; Sarkisova Y; Sun F; Steffy A; Pferdekamper AC; Li AG; Joseph SB; Kim Y; Liu B; Tuntland T; Cui X; Gray NS; Steensma R; Wan Y; Jiang J; Chopiuk G; Li J; Gordon WP; Richmond W; Johnson K; Chang J; Groessl T; He YQ; Phimister A; Aycinena A; Lee CC; Bursulaya B; Karanewsky DS; Seidel HM; Harris JL; Michellys PY
J Med Chem; 2013 Jul; 56(14):5675-90. PubMed ID: 23742252
[TBL] [Abstract][Full Text] [Related]
20. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
Mologni L; Ceccon M; Pirola A; Chiriano G; Piazza R; Scapozza L; Gambacorti-Passerini C
Oncotarget; 2015 Mar; 6(8):5720-34. PubMed ID: 25749034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
